Effectiveness and Safety of Nivolumab in Child-Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study

Cancers
Won-Mook ChoiJonggi Choi

Abstract

Nivolumab has shown durable response and safety in patients with hepatocellular carcinoma (HCC) in previous trials. However, real-world data of nivolumab in HCC patients, especially those with Child-Pugh class B, are limited. To investigate the effectiveness and safety of nivolumab in a real-world cohort of patients with advanced HCC, we retrospectively evaluated 203 patients with HCC who were treated with nivolumab between July 2017 and February 2019. Of 203 patients, 132 patients were classified as Child-Pugh class A and 71 patients were Child-Pugh class B. Objective response rate was lower in patients with Child-Pugh class B than A (2.8% vs. 15.9%; p = 0.010). Child-Pugh class B was an independent negative predictor for objective response. Median overall survival was shorter in Child-Pugh B patients (11.3 vs. 42.9 weeks; adjusted hazard ratio [AHR], 2.10; p < 0.001). In Child-Pugh B patients, overall survival of patients with Child-Pugh score of 8 or 9 was worse than patients with Child-Pugh score of 7 (7.4 vs. 15.3 weeks; AHR, 1.93; p < 0.020). In conclusion, considering the unsatisfactory response in Child-Pugh B patients, nivolumab may not be used in unselected Child-Pugh B patients. Further studies are needed in this pat...Continue Reading

References

Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Feb 23, 2010·Seminars in Liver Disease·Riccardo Lencioni, Josep M Llovet
Nov 1, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Zhigang TianBin Gao
Apr 15, 2014·Nature Medicine·Alastair J O'BrienDerek W Gilroy
Aug 20, 2014·Journal of Hepatology·Agustín AlbillosMelchor Álvarez-Mon
Dec 9, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Won Hyeok Choe, Soon Koo Baik
Jun 24, 2015·Gastroenterology·Jessica Zucman-RossiJosep M Llovet
Dec 19, 2017·Clinical and Molecular Hepatology·Bo Hyun Kim, Joong-Won Park
Apr 7, 2018·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jorge A MarreroJulie K Heimbach
Jul 25, 2018·Alimentary Pharmacology & Therapeutics·Matthias Pinter, Markus Peck-Radosavljevic
Oct 31, 2018·Journal of Cancer Research and Clinical Oncology·Fabian FinkelmeierOliver Waidmann
Nov 2, 2018·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Mairéad Geraldine McNamaraEitan Amir
Jun 10, 2019·Journal of Hepatology·Thomas YauMasatoshi Kudo
Dec 4, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard S FinnUNKNOWN KEYNOTE-240 investigators
Oct 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A VogelUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
May 14, 2020·The New England Journal of Medicine·Richard S FinnUNKNOWN IMbrave150 Investigators

❮ Previous
Next ❯

Citations

Apr 4, 2021·Pharmaceuticals·Piera FedericoBruno Daniele
Jul 3, 2021·Journal of Clinical Medicine·Anne Dyhl-PolkDorte Lisbet Nielsen

❮ Previous
Next ❯

Software Mentioned

mRECIST
R

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.